Coronary heart disease (CHD) is the leading cause of death in developed countries. Gender has a significant influence on the cause, clinical manifestation and prognosis of CHD. Men develop CHD approximately 10 to 15 years earlier than women. Non-modifiable CHD risk factors such as age and family history have a different effect in men than in women. Modifiable risk factors also show differences between the sexes. Smoking is more prevalent and hypertension less controlled in men. Overweight and obesity appear to be more potent risk factors in men, and the higher prevalence of abdominal obesity in men increases their risk for CHD. According to some studies this could explain gender differences in the incidence of CHD but women’s significant protection against CHD during their reproductive years could be another explanation. Myocardial infarction is usually the first manifestation of CHD in men and the risk of its recurrence is twice as high in men as in women. A robust database provides evidence that routine thorough cardiovascular risk assessment in men over 40 years of age and in postmenopausal females is a prudent procedure. Lifestyle changes and timely and aggressive therapy for lipid disorders, hypertension and diabetes mellitus can improve the prognosis of high-risk patients.
Get full access to this article
View all access options for this article.
References
1.
WengerNK. Gender differences in coronary risk and risk factors. In: MansonJEet al., editors. Prevention of myocardial infarction. New York: Oxford University Press; 1996. p. 387–412.
2.
Results of systematic review of research on diagnosis and treatment of coronary heart disease in women. Summary, evidence report/technology assessment: number 80. AHRQ Publication No. 03-E034, May2003.
3.
OrenciaA., BaileyK., YawnB.P., KottkeT.E.Effect of gender on long-term outcome of angina pectoris and myocardial infarction/sudden unexpected death. J Am Med Assoc, 1993; 269(18):2392–2397.
4.
Executive summary of the third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc, 2001; 285:2486–97.
5.
ThomTJ, KannelWB, SilbershatzS, et al.Incidence, prevalence, and mortality of cardiovascular diseases in the United States. In: AlexanderRW, SchlantRC, FusterV, RobertsR, editors. Hurst’s The Heart. 9th ed. New York: McGraw Hill; 1998. p. 3.
6.
LeviF., LucchiniF., NegriE., La VecchiaC.Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart, 2002; 88(2):119–124.
7.
KannelW.B.The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med, 2002; 5(2):27–37.
8.
LernerD.J., KannelW.B.Patterns of coronary heart disease morbidity and mortality in the sexes: 26-year follow-up of the Framingham population. Am Heart J, 1986; 111(2):383–390.
9.
American Heart Association. Heart Disease and Stroke Statistics—2004 Update. National Centre, 7272 Greenville Avenue, Dallas, Texas 75231-4596, online at www.americanheart.org/presenter/downloadable/heart.
10.
PrescottE., HippeM., SchnohrP., et al.Smoking and the risk of myocardial infarction in women and men: longitudinal population study. Br Med J, 1998; 316:1043–1047.
European Countries Profile on Tobacco Control 2001. Copenhagen: WHO Regional Office; 2002.
13.
ChobanianA.V., BakrisG.L., BlackH.R., et al.The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. J Am Med Assoc, 2003; 289(19):2560–2571.
14.
KaplanNM. Hypertension in the population at large, gender and risk. In: Clinical hypertension. 5th ed. Williams & Wilkins. p. 3.
15.
JoffresMR, GhadirianP, FodorJG, PetrasovitsA, ChokalingamA, HametP.Awareness, treatment, and control of hypertension in Canada. Am J Hypertens, 1997; 10:1097–102.
16.
GenestJ, FrohlichJ, FodorG, McPhersonR, The Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease. CMAJ, 2003; 169(October (9)):921–4.
17.
KannelW., McGeeD.Diabetes and cardiovascular risk factors: The Framingham Study. Circulation, 1979; 59(1):8–13.
18.
CoutinhoM., GersteinH.C., WangY., YusufS.The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care, 1999; 22(2):233–240.
19.
KaplanN.M.Obesity, insulin and hypertension. Cardiovasc Risk Factors, 1994; 4:133–139.
20.
LarssonB., BengtsonC., BjorntorpP., LapidusL., SjostromL., SvarsuddK., et al.Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Goteborg, Sweden. Am J Epidemiol, 1992; 135:266–273.
21.
LakkaH.M., LaaksonenD.E., LakkaT.A., et al.The metabolic syndrome and total and cardiovascular disease in middle-aged men. J Am Med Assoc, 2002; 288:2709–2716.
22.
PowellK.E., ThompsonP.D., CaspersenC.J., KendrickJ.S.Physical activity and the incidence of coronary heart disease. Annu Rev Public Health, 1987; 8:253–287.
23.
PaffenbargerR.S.Jr., HydeR.T., WingA.L., LeeI.M., JungD.L., KampertJ.B.The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med, 1993; 328(8):538–545.
24.
MoriseA.P., DalalJ.N., DuvalR.D.Value of a simple measure of estrogen status for improving the diagnosis of coronary artery disease in women. Am J Med, 1993; 94(5):491–496.
25.
Writing Group for the Women’s Health Initiative Randomized Controlled Trial. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. J Am Med Assoc, 2002; 288:321–33.
26.
GyllenborgJ., RasmussenS.L., Borch-JohnsenK., HeitmannB.L., SkakkebaekN.E., JuulA.Cardiovascular risk factors in men: the role of gonadal steroids and sex hormone-binding globulin. Metabolism, 2001; 50(8):882–888.
27.
EnglishK.M., MandourO., SteedsR.P., DiverM.J., JonesT.H., ChannerK.S.Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J, 2000; 21:890–894.
28.
EnglishK.M., SteedsR.P., JonesT.H., DiverM.J., ChannerK.S.Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized double blind placebo-controlled study. Circulation, 2000; 102:1906–1911.
29.
ZmudaJ.M., CauleyJ.Á., KriskaA., GlynnN.W., GuptaiJ.P., KullerL.H.Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men: a 13-year follow-up of former Multiple Factor Intervention Trial participants. Am J Epidemiol, 1997; 146:609–617.
30.
RimmE.B., GiovannucciE.L., WillettW.C., ColditzG.A., AscherioA., RosnerB., StampferM.J.Prospective study of alcohol consumption and risk of coronary disease in men. Lancet, 1991; 338(8765):464–468.
31.
StecJ.J., SilbershatzH., ToflerG.H., MatheneyT.H., SutherlandP., LipinskaI., et al.Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation, 2000; 102(14):1634–1638.
32.
ArnoldA.L., MilnerK.A., VaccarinoV.Sex and race differences in electrocardiogram use (The National Hospital Ambulatory Medical Care survey). Am J Cardiol, 2001; 88(9):1037–1040.
